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OBJECTIVE — Genetic factors have been considered to contribute to the development and
progressionofdiabeticnephropathy.TheKCNQ1gene(potassiumvoltage-gatedchannel,KQT-
like subfamily, member 1) was originally identiﬁed as a strong susceptibility gene for type 2
diabetes in two Japanese genome-wide association studies. In this study, we examined the
association of single nucleotide polymorphisms (SNPs) within KCNQ1 with diabetic nephrop-
athy in Japanese subjects with type 2 diabetes.
RESEARCHDESIGNANDMETHODS — Wegenotyped33SNPsinKCNQ1using754
type 2 diabetic patients with overt nephropathy and 558 control subjects (an initial study), and
we further examined the association of a candidate SNP using three other independent Japanese
populations (replications 1–3).
RESULTS — WefoundthatﬁveSNPswerenominallyassociatedwithdiabeticnephropathy,and
the association of rs2237897 was the strongest. We also found that the T allele frequencies of
rs2237897 were consistently higher in the nephropathy groups than in the control groups for all
studypopulations(initialstudy:0.33vs.0.27;replication1:0.32vs.0.30;replication2:0.33vs.0.28;
and replication 3: 0.32 vs. 0.28), although the individual associations did not reach statistically
signiﬁcant levels. Combined analysis by a meta-analysis revealed that the T allele of rs2237897 was
signiﬁcantly associated with susceptibility to diabetic nephropathy in Japanese subjects with type 2
diabetes (odds ratio 1.22 [95% CI 1.10–1.34], P  3.1  10
–4, corrected P  0.01).
CONCLUSIONS — TheseresultssuggestthatKCNQ1isanewcandidategeneforconferring
susceptibility to diabetic nephropathy.
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D
iabeticnephropathyisaseriousmi-
crovascular complication of diabe-
tes, and it is a leading cause of end-
stage renal disease in western countries
(1) and in Japan (2). Several genetic and
environmental factors are likely to con-
tribute to its development and progres-
sion (3,4), but the precise mechanism for
this contribution is unknown.
The recent genome-wide association
studies using Japanese populations led to
the identiﬁcation of the KCNQ1 (potas-
sium voltage-gated channel, KQT-like
subfamily, member 1) gene as a novel
gene for susceptibility to type 2 diabetes
(5,6). KCNQ1 encodes the pore-forming
 subunit of the voltage-gated potassium
channelexpressedmainlyintheheart(7).
The mutations of KCNQ1 have been
known to cause hereditary long QT syn-
dromes (Romano-Ward syndrome [8]
and Jervell and Lange-Nielsen syndrome
[9]), which are characterized by the pro-
longation of QT intervals on the electro-
cardiogram; in some instances, these
syndromes cause sudden cardiac death in
the young (10) through the loss of func-
tionofthepotassiumchannelintheheart.
The expression of KCNQ1 could also be
observedinthehumankidney.Inthekid-
ney,KCNQ1hasbeenshowntoassemble
with KCNE1, the  subunit of the potas-
sium channel, forming a potassium chan-
nelcomplexlocalizedtothebrushborder
of the mid to late proximal tubule
(11,12); moreover, it has been shown to
play a role in the Na
 secretion at the
proximal tubule by maintaining a driving
force for Na
 transport across the mem-
brane (13). In previous studies, kcnq1
knockout mice were reported to show
lower blood pressure (14). These obser-
vations suggest the possibility that
KCNQ1 is a candidate for conferring sus-
ceptibility to diabetic nephropathy. To
test this hypothesis, we focused on
KCNQ1 as a candidate gene for diabetic
nephropathy and investigated the associ-
ation between the single nucleotide poly-
morphisms (SNPs) within KCNQ1 and
diabetic nephropathy in Japanese sub-
jects with type 2 diabetes.
RESEARCH DESIGN AND
METHODS
DNA preparation and SNP
genotyping
For the initial study, DNA samples were
obtained from the peripheral blood of pa-
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versity of Medical Science, Tokyo Wom-
en’s Medical University, Juntendo
University, Kawasaki Medical School,
Iwate Medical University, Toride Kyodo
Hospital, Kawai Clinic, Osaka City Gen-
eral Hospital, Chiba Tokushukai Hospi-
tal, or Osaka Rosai Hospital. All subjects
provided informed consent before enroll-
ing in this study. Diabetes was diagnosed
according to the World Health Organiza-
tion criteria. Type 2 diabetes was clini-
cally deﬁned as a disease with gradual
adult onset. Subjects who tested positive
for anti-GAD antibodies and those with
mitochondrial disease (mitochondrial
myopathy, encephalopathy, lactic acido-
sis, and stroke-like episodes) or maturity-
onsetdiabetesoftheyoung(MODY)were
not included. DNA was extracted by a
standard phenol-chloroform method. Di-
abetic patients were divided into two
groups according to the following diag-
nostic criteria: 1) the nephropathy group
(n  754) comprised patients with dia-
betic retinopathy and overt nephropathy
indicated by a urinary albumin excretion
rate (AER) 200 g/min or a urinary al-
bumin-to-creatinine ratio (ACR) 300
mg/g creatinine; and 2) the control group
(n  558) comprised patients with dia-
betic retinopathy but with no evidence of
renal dysfunction (i.e., AER 20 g/min
or ACR 30 mg/g creatinine). Measure-
ments of AER or ACR were performed at
least twice for each patient. The genotype
of 33 SNPs within KCNQ1 was analyzed
with multiplex PCR-Invader assays as de-
scribed previously (15–17). The statisti-
cal power of the initial study was
estimated to be 0.35 for SNPs with minor
allele frequency of 0.3, if we set a cutoff
value at the P  0.0015 level (signiﬁcant
level after Bonferroni correction) and a
genotypic relative risk () of 1.2 and the
prevalence of diabetic nephropathy is as-
sumed to be 10%. All patients participat-
ing in this study provided written
informed consent, and the study protocol
was approved by the ethics committees of
RIKEN Yokohama Institute and each par-
ticipating institution.
Subjects in replication studies
Replication 1, BioBank Japan case-
control study. We selected diabetic ne-
phropathy case and control samples from
the subjects enrolled in BioBank Japan.
Nephropathywasdeﬁnedaspatientswith
type2diabeteshavingbothovertdiabetic
nephropathy and diabetic retinopathy
(n  449). The control subjects included
patients with type 2 diabetes having dia-
betic retinopathy and normoalbuminuria
(n  965). All patients participating in
this study provided written informed
consent, and the study protocol was ap-
proved by the ethics committees of
RIKEN Yokohama Institute.
Replication 2, Tokai University case-
control study. Patients with type 2 dia-
betes regularly visiting Tokai University
Hospitaloritsafﬁliatedhospitalswereen-
rolled. All nephropathy patients were re-
ceiving chronic hemodialysis therapy,
and control patients included those with
normoalbuminuriadeterminedbyatleast
two measurements of the urinary ACR
and with diabetes for 	10 years (case
subjects, n  310; control subjects, n 
224). All patients provided written in-
formed consent, and the protocol was ap-
proved by the ethics committees of Tokai
UniversitySchoolofMedicineandRIKEN
Yokohama Institute.
Replication 3, Shiga prospective study.
Patients with type 2 diabetes were re-
cruited from among the participants of
the Shiga Prospective Observational Fol-
low-Up Study for Diabetic Complications
(18). Patients classiﬁed as having mi-
croalbuminuria (200 g/ml 	 AER 20
g/min) on the basis of at least two mea-
surements of AER in 24-h urine collec-
tions were followed for up to 6 years. The
progressors (case subjects, n  32) were
deﬁned as those who had progressed to
overt proteinuria (AER 200 g/min),
and the remaining patients were deﬁned
as nonprogressors (control subjects, n 
168). The study protocol and informed
consent procedure were approved by the
ethics committees of Shiga University of
Medical Science and RIKEN Yokohama
Institute.
Theclinicalcharacteristicsofsubjects
are shown in supplementary Table A1




We tested the genotype and allele fre-
quencies for Hardy-Weinberg equilib-
rium proportions by the 

2 test (19). We
calculated the linkage-disequilibrium in-
dex, D,a n dr
2 as described elsewhere
(20). We analyzed the differences be-
tween the case and control groups in
terms of the distribution of genotypes
scored with an additive model by using a
logistic regression analysis with or with-
out adjustment for age, sex, BMI, and du-
ration of type 2 diabetes. A haplotype
structurewithintheKCNQ1locuswasan-
alyzed by using Haploview software, ver-
sion 4.1 (21). Combined meta-analysis
was performed by using the Mantel-
Haenszel procedure with a ﬁxed-effects
model after testing for heterogeneity.
RESULTS— We ﬁrst examined the as-
sociation of 33 SNPs within the KCNQ1
susceptibility locus for type 2 diabetes
with diabetic nephropathy in Japanese
subjects with type 2 diabetes (initial
study: case subjects, n  754; control
subjects, n  558). The genotype distri-
butions for all except two SNPs
(rs234881 [P  0.046] in case subjects
and rs2283228 [P  0.029] in control
subjects) (supplementary Table A2, avail-
able in an online appendix) did not
deviate from the Hardy-Weinberg equi-
librium.WeidentiﬁedﬁveSNPsthatwere
signiﬁcantly associated with diabetic ne-
phropathy (nominal P  0.05). Among
them, the T allele of rs2237897 was the
moststronglyassociatedwithsusceptibil-
ity to the disease (unadjusted odds ratio
[OR] 1.30 [95% CI 1.09–1.54], P 
0.0027; OR adjusted for age, sex, BMI,
and duration of diabetes 1.33 [1.08–
1.63], P  0.008) (Table 1, Fig. 1, sup-
plementary Table A3, available in an
onlineappendix).Wealsofoundthatage,
sex (male), and duration of type 2 diabe-
tes were independent risk factors for dia-
betic nephropathy in this analysis (data
not shown). Subsequent analysis for the
haplotype structure within this locus re-
vealed that none of the haplotypes were
morestronglyassociatedwithdiabeticne-
phropathy than the single SNP alone
(rs2237897) (supplementary Table A4,
available in an online appendix).
We also examined the association of
rs2237897 with hypertension. In this
analysis, we divided subjects with type 2
diabetes into two groups: 1) hypertensive
group, comprising subjects with systolic
blood pressure 140 mmHg and/or dia-
stolic blood pressure 90 mmHg or sub-
jects taking antihypertensive agents and
2) the normotensive group, comprising
subjects with systolic blood pressure
140 mmHg and diastolic blood pres-
sure 90 mmHg without taking any an-
tihypertensive agent. The result indicated
that rs2237897 was not signiﬁcantly as-
sociated with hypertension (OR 1.19
[95% CI 0.90–1.58], P  0.23).
rs2237897 was also not associated with
plasma glucose or A1C in subjects with
type 2 diabetes (data not shown).
Theassociationofrs2237897withdi-
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tically signiﬁcant levels after Bonferroni
correction, probably due to insufﬁcient
studypowertodetectatrueassociationin
the initial study (see RESEARCH DESIGN AND
METHODS). Therefore, to validate the asso-
ciation of the T allele of rs2237897, we
further examined the association of
rs2237897 with diabetic nephropathy in
threeotherindependentstudies(BioBank
Japan case-control study, replication 1:
case subjects, n  449; control subjects,
n  965; Tokai University case-control
study, replication 2: case subject, n 
310;controlsubjects,n224;Shigapro-
spective study, replication 3: progression
case subjects, n  32; control subjects,
n  168). The results revealed that the T
allelefrequenciesofrs2237897werecon-
sistently higher in the case groups than in
the control groups (replication 1: 0.32 vs.
0.30;replication2:0.33vs.0.28;andrep-
lication 3: 0.32 vs. 0.28), although the
individual associations did not reach sta-
tisticallysigniﬁcantlevels(Table2).Com-
binedanalysisbyameta-analysiswiththe
Mantel-Haenszel test revealed that the T
alleleofrs2237897wassigniﬁcantlyasso-
ciated with susceptibility to diabetic ne-
phropathy(proteinuria:OR1.21[95%CI
1.08–1.36], P  1.4  10
–3, corrected
P  0.046; proteinuria plus end-stage re-
nal disease: 1.22 [1.10–1.34], P  3.1 
10
–4, corrected P  0.01) (Table 2).
CONCLUSIONS — In the present
study,wefoundthatanSNP(rs2237897)
within KCNQ1 was associated with sus-
ceptibility to diabetic nephropathy in a
Japanese population. The same trend of
the association of rs2237897 was consis-
tently observed in three additional repli-
cation studies, and the association was
found to be statistically signiﬁcant by a
meta-analysis (corrected P  0.01).
KCNQ1, located in 11p15.5, encodes
the  subunit of the voltage-gated potas-
sium channel that is mainly expressed in
the heart, inner ear, and to a lesser extent
in the stomach, intestine, liver, and kid-
ney (7). In the kidney, KCNQ1 assembles
withKCNE1toformapotassiumchannel
complexthatislocalizedtothebrushbor-
der of the mid to late proximal tubule
(11,12).Thispotassiumchannelhasbeen
showntoberesponsibleformaintaininga
driving force for Na
 reabsorption by the
repolarization of the membrane and to af-
fect Na
 secretion at the proximal tu-
bule (13). Therefore, KCNQ1 may be
considered as a plausible candidate for
conferring susceptibility to diabetic
nephropathy.
Our present study revealed that the T
allele of rs2237897 in KCNQ1 was the
moststronglyassociatedwithsusceptibil-
ity to diabetic nephropathy, and no other
SNP or haplotype was more strongly as-
sociated with the disease than rs2237897
alone in our Japanese populations. Fur-
thermore, in our previous genome-wide
association study for type 2 diabetes, we
demonstrated that rs2237897 was also
the most strongly associated with type 2
diabetes (5); therefore, it is likely that
rs2237897 could directly contribute to
the susceptibility to diabetic nephropa-
thy, although the mechanism underlying
the contribution of this variation is
unknown.
From cumulative evidence, it is well
known that poor glycemic control and/or
Figure 1—Association of the SNPs within KCNQ1 in the initial study. P values for each SNP,
calculated by a logistic regression analysis, are plotted. A: Unadjusted data. B: Data adjusted for
age,sex,BMI,anddurationoftype2diabetes.– – –,Nominallysigniﬁcantlevel(P0.05);——,
statistically signiﬁcant level after Bonferroni adjustment (P  0.0015).
Table 1—SNPs nominally associated with diabetic nephropathy in the initial study
SNP Risk allele
Unadjusted Adjusted*
P OR (95% CI) P OR (95% CI)
rs123381 G 0.036 1.24 (1.02–1.52) 0.012 1.39 (1.08–1.79)
rs163183 C 0.014 1.78 (1.13–2.81) 0.328 1.32 (0.76–2.11)
rs2299620 T 0.022 1.21 (1.03–1.42) 0.074 1.20 (0.98–1.46)
rs2237896 A 0.019 1.22 (1.03–1.44) 0.082 1.20 (0.98–1.47)
rs2237897 T 0.0027 1.30 (1.09–1.54) 0.008 1.33 (1.08–1.63)
*Adjusted for age, sex, BMI, and duration of type 2 diabetes.
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gression of nephropathy in patients with
diabetes. Because rs2237897 was origi-
nally shown to be associated with type 2
diabetes as well as with insulin secretion
or fasting plasma glucose in subjects with
normal glucose tolerance (22,23), the ef-
fects of rs2237897 on conferring suscep-
tibility to diabetic nephropathy might be
mediated by a difference in glycemic con-
trol according to the genotype. In our
present study, however, rs2237897 was
not associated with plasma glucose or
A1C in subjects with type 2 diabetes, and
the association between rs2237897 and
diabetic nephropathy was not affected by
adjusting A1C in the logistic regression
analysis. Moreover, the T allele of
rs2237897, a risk allele for diabetic ne-
phropathy in the present study, was
shown to be a nonrisk allele for type 2
diabetes, reduction of insulin secretion,
orelevationofbloodglucoselevel.There-
fore, it is suggested that rs2237897 con-
tributes to conferring susceptibility to
diabetic nephropathy through a mecha-
nism independent of glycemic control.
There may be a possibility that
rs2237897 affects systemic blood pres-
sure because KCNQ1 has been shown to
play some roles in the regulation of renal
Na
 reabsorption as described above. To
evaluate this possibility, we also exam-
ined the association of rs2237897 with
hypertension using 1,312 subjects with
type 2 diabetes (initial study). The result
indicated that rs2237897 was not signiﬁ-
cantly associated with hypertension (OR
1.19 [95% CI 0.90–1.58], P  0.23). In
addition, a nominal association of
rs2237897 with diabetic nephropathy
could also be observed by a logistic re-
gressionanalysisusingthepresenceofhy-
pertension or systolic and/or diastolic
blood pressures as covariables (data not
shown). Therefore, it is likely that the ef-
fect of rs2237897 is also independent of
systemic blood pressure.
In previous studies, subjects with a
loss-of-function mutation of KCNQ1 and
kcnq1 knockout mice did not exhibit glu-
cose intolerance (14). In contrast, it was
reported that an inhibitor of KCNQ1
(chromanol 293B) signiﬁcantly increased
insulin secretion in the presence of sulfo-
nylurea (24); this ﬁnding suggested that
theactivityofKCNQ1insubjectswiththe
Calleleofrs2237897,ariskallelefortype
2 diabetes, might be higher than that in
subjects with the T allele, a risk allele for
diabetic nephropathy in the present
study. However, further studies will be
required to elucidate the precise molecu-
lar mechanism by which KCNQ1 and its
polymorphism contribute to susceptibil-
ity to diabetic nephropathy.
In summary, we found that the T al-
lele of rs2237897 within KCNQ1 was sig-
niﬁcantlyassociatedwithsusceptibilityto
diabeticnephropathyinJapanesepopula-
tions. The present data suggest that
KCNQ1 may be a good candidate for dia-
betic nephropathy and a target to develop
new drugs for treatment of the disease.
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